Ovarian, fallopian tube and peritoneal cancer (BRCA 1 or 2, mutated, relapsed, platinum-sensitive) - olaparib (maintenance) [ID735]: committee papers 2

Table of contents

 

01. [Consultee/Commentator] comments on the ACD – AstraZeneca

03. [Consultee/Commentator] comments on the ACD – British Gynaecological Cancer Society

04. Consultee comments on the ACD – Ovarian Cancer Action

05. Consultee commnbts on the ACD – Ovacome

06. Consultee commebts on the ACD – NCRI-RCP-RCR-ACP

07. Consultee comments on the ACD – Target Ovarian Cancer 

08. Public comments on the ACD received via the NICE website  

09 - Evidence Review Group response to ACD prepared by School of related Health  Research

This page was last updated: 07 August 2015